Langerhans cells that express matrix metalloproteinase 9 increase in human dermis during sensitization to diphenylcyclopropenone in patients with alopecia areata

Multiscale modelling of relationships between protein classes and drug behavior across all diseases using the CANDO platform

We have examined the effect of eight different protein classes (channels, GPCRs, kinases, ligases, nuclear receptors, proteases, phosphatases, transporters) on the benchmarking performance of the CANDO drug discovery and repurposing platform (http://protinfo.org/cando). The first version of the CANDO platform utilizes a matrix of predicted interactions between 48278 proteins and 3733 human ingestible compounds (including FDA approved drugs and supplements) that map to 2030 indications/diseases using a hierarchical chem and bio-informatic fragment based docking with dynamics protocol (> one billion predicted interactions considered). The platform uses similarity of compound-proteome interaction signatures as indicative of similar functional behavior and benchmarking accuracy is calculated across 1439 indications/diseases with more than one approved drug. The CANDO platform yields a significant correlation (0.99, p-value < 0.0001) between the number of proteins considered and benchmarking accuracy obtained indicating the importance of multitargeting for drug discovery. Average benchmarking accuracies range from 6.2 % to 7.6 % for the eight classes when the top 10 ranked compounds are considered, in contrast to a range of 5.5 % to 11.7 % obtained for the comparison/control sets consisting of 10, 100, 1000, and 10000 single best performing proteins. These results are generally two orders of magnitude better than the average accuracy of 0.2% obtained when randomly generated (fully scrambled) matrices are used. Different indications perform well when different classes are used but the best accuracies (up to 11.7% for the top 10 ranked compounds) are achieved when a combination of classes are used containing the broadest distribution of protein folds. Our results illustrate the utility of the CANDO approach and the consideration of different protein classes for devising indication specific protocols for drug repurposing as well as drug discovery.

The role of lymphocytes in the development and treatment of alopecia areata

Alopecia areata (AA) development is associated with both innate and adaptive immune cell activation, migration to peri- and intra-follicular regions, and hair follicle disruption. Both CD4(+) and CD8(+) lymphocytes are abundant in AA lesions; however, CD8(+) cytotoxic T lymphocytes are more likely to enter inside hair follicles, circumstantially suggesting that they have a significant role to play in AA development. Several rodent models recapitulate important features of the human autoimmune disease and demonstrate that CD8(+) cytotoxic T lymphocytes are fundamentally required for AA induction and perpetuation. However, the initiating events, the self-antigens involved, and the molecular signaling pathways, all need further exploration. Studying CD8(+) cytotoxic T lymphocytes and their fate decisions in AA development may reveal new and improved treatment approaches.

Tissue inhibitors of matrix metalloproteinase-1 levels are increased in serum of patients with allergic contact dermatitis

Allergic contact dermatitis (ACD) is an antigen-specific, T-cell-mediated skin inflammatory disease. Matrix metalloproteinases (MMPs) and their tissue inhibitors of matrix metalloproteinases (TIMPs) play a role in degradation of extracellular matrix and subsequent tissue remodelling during inflammatory process. The objective of this study was to examine a possible role of TIMP-1 and MMP-9 in the pathogenesis of ACD. The serum levels of MMP-9 and TIMP-1 have been measured using enzyme-linked immunosorbent assay in patients with disseminated ACD during exacerbation of skin lesions and the remission stage (n= 20) and were compared with healthy subjects (n= 20). The mean serum levels of TIMP-1 were significantly higher in patients with ACD than in control group (42.8 +/- 4.9 ng/ml). This difference was more prominent in patients with ACD during remission (69.01 +/- 6.99 ng/ml, P < 0.0001) than in patients with exacerbation of disease (46.8 +/- 3.6 ng/ml, P= 0.0054). Mean values of serum MMP-9 did not differ significantly between patients with ACD, both in the acute and in the remission stage, compared with healthy persons (P= 0.76 and P= 0.29, respectively). TIMP-1 might be involved in pathogenesis of ACD. It seems that moderately increased levels of TIMP-1 could reflect degree of activity of skin inflammation, whereas markedly increased levels could contribute to the maintenance of the remission of disease.